SBIR Phase I: Novel High Voltage Pulsed Power Supplies for Nanosecond Repetitively Pulsed Plasmas

SBIR 第一阶段：用于纳秒重复脉冲等离子体的新型高压脉冲电源

• 批准号: 1622230
• 负责人: Luke Raymond
• 金额: $ 22.5万
• 依托单位: Airity Technologies
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1622230&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; Voltage; Pulsed

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is the development of a medical device that accelerates wound healing and prevents infection. Wound contamination and infection are notoriously challenging to treat and are a significant cause of patient morbidity and mortality. Bacterial and other microbial colonization in wounds delay healing, cause further degradation, and can lead to severe complications including deep tissue and bone infections, as well as stroke and sepsis. The wound care field is large and diverse and includes acute and chronic wounds, pre- and post-surgical care and scar prevention, burns, as well as emergency wound care in war settings and homeland security. Due to the aging population and increasing rates of diabetes and obesity, the entire global wound care products market is expanding rapidly at an estimated 7% per year and currently totals over $21B. Moreover, new financial reimbursement policies to reduce the estimated $50B US economic burden of wounds are incentivizing hospitals to improve care, reduce infection, and accelerate patient recovery. The market is ripe for a medical technology that treats wound infections.This Small Business Innovation Research (SBIR) Phase I project supports the development of a high voltage power supply capable of driving a cold plasma medical device that treats wound infections. Cold plasma is ideal for treating wound infections because it is effective against all bacteria types and is unlikely to confer bacterial resistance. It is superior in its anti-microbial effect compared to topical antibiotics and antiseptics but safe for human skin. Our research objectives include scaling the output voltage, shortening pulse width, enabling thermal, overvoltage, and overcurrent protections, and incorporating voltage control feedback. Anticipated technical results include completion of these research objectives and testing of the power supply with the cold plasma device on bacterial cultures to confirm antibacterial effects.

这项小型企业创新研究（SBIR）I期项目的更广泛的影响/商业潜力是开发一种医疗装置，可加速伤口愈合并防止感染。 众所周知，伤口污染和感染是挑战性的，是患者发病率和死亡率的重要原因。伤口中的细菌和其他微生物定殖延迟愈合，导致进一步的降解，并可能导致严重的并发症，包括深层组织和骨骼感染以及中风和败血症。伤口护理领域大而多样化，包括急性和慢性伤口，手术前后护理和预防疤痕，烧伤以及战争环境和国土安全部的紧急伤口护理。由于人口老龄化以及糖尿病和肥胖症发生率的增加，整个全球伤口护理产品市场的迅速增长，估计为每年7％，目前总计超过21B美元。此外，新的金融报销政策减少了估计$ 50B的美国伤口经济负担，正在激励医院改善护理，减少感染并加速患者的康复。该小型企业创新研究（SBIR）I阶段项目支持一种医疗技术，该市场已经成熟。冷等离子体是治疗伤口感染的理想选择，因为它对所有细菌类型有效，并且不太可能赋予细菌耐药性。与局部抗生素和防腐剂相比，它的抗菌作用优越，但对人皮肤安全。我们的研究目标包括扩展输出电压，缩短脉冲宽度，使热量，过电压和过电流保护以及结合电压控制反馈。预期的技术结果包括完成这些研究目标以及使用冷等离子体设备在细菌培养物上测试电源以确认抗菌作用。